San Martín, R., et al. Structure and immunological activity of QS-21 variant from Quillaja saponaria aerial biomass. Front Immunol, 2026 Mar 9, 17:1771912, PMID: 41878432

•  This study focuses on QS-21, a potent saponin adjuvant essential for human
  vaccines, traditionally sourced from the bark of mature Quillaja saponaria trees in
  Chile. The researchers identified a natural variant, QS-21-Rha, predominantly found
  in the leaves and twigs of young California-grown shrubs, which can be extracted
  with high purity. Importantly, QS-21-Rha exhibits immunological activity comparable
  or superior to bark-derived QS-21, particularly in activating CD4+ T cells. This
  discovery offers a promising, eco-friendly, and scalable source of vaccine adjuvant,
  potentially enhancing supply chain resilience, reducing environmental harm, and
  lowering manufacturing costs, which are crucial factors for expanding global vaccine
  access.
•  The main results of the study demonstrate that QS-21-Rha, a naturally occurring
  variant isolated from the leaves and twigs of young Quillaja saponaria shrubs grown
  in California, can be produced in high purity and yields from renewable plant
  material. Structurally, QS-21-Rha differs from traditional bark-derived QS-21 by the
  substitution of rhamnose at the C3 position of the glycoside moiety. Immunologically,
  QS-21-Rha formulated into liposomes elicits robust adaptive immune responses,
  notably strong activation of CD4+ T cells and increased cytokine production, often
  exceeding the responses induced by traditional QS-21. Additionally, the production
  of QS-21-Rha requires significantly less biomass and is more environmentally
  sustainable, offering advantages in scalability, quality control, and cost-effectiveness
  for vaccine manufacturing.
• Comment from DK: Despite the advantages of QS-21-Rha described in this paper,
  the traditional QS-21 has been extensively characterized and has an established
  safety and efficacy profile based on numerous preclinical and clinical studies. Its
  well-understood mechanisms of action, stability, and compatible formulation with
  existing vaccine platforms provide a significant advantage in translational
  development and regulatory approval processes. Additionally, the complex mixture
  of isomers present in traditional bark-derived QS-21 may offer a broader range of
  immunostimulatory properties, which could be beneficial for certain vaccine
  formulations or disease targets. The single-isomer composition and defined
  chemical structure of QS-21-Rha could potentially limit some of the broader
  immunostimulatory effects that the mixture of isomers in traditional QS-21 might
  confer. Moreover, as the field is more familiar with the long-term safety and
  immunogenicity data of traditional QS-21, regulatory pathways may be more
  straightforward for its use, whereas QS-21-Rha would require additional validation.
  In summary, the traditional QS-21's comprehensive safety profile, established
  efficacy, and formulation stability may make it still preferable in certain contexts,
  even if QS-21-Rha shows promising immunological benefits.

Click here to access the full scientific paper.